frovatriptan / Generic mfg. - LARVOL DELTA

Ease of intubation using oral Microcuff RAE (Ring-Adair-Elwyn) tube with and without premounted Frova intubating introducer in children undergoing cleft lip and palate surgeries - A randomised controlled study. (PubMed, Indian J Anaesth) - "There was no difference in the requirement of ELMs (13 vs. 17, P = 0.261), and the ease of intubation was also comparable. Frova introducer-guided endotracheal intubation with an oral RAE tube does not decrease intubation time in children undergoing cleft lip and palate surgery."

Intubation • Journal

Improving beta-amyloid PET productivity: Exploring early and short acquisition windows for 18F-NAV4694 PET to increase clinical throughput. (SNMMI 2025) - " 38 AIBL participants underwent dynamic 18F-NAV4694 imaging on a Philips Allegro scanner... For each regression, the equation and coefficient of determination (R2) were: estCL50-70 = 1.03 CL50-60 + 0.83 (R2=0.999). estCL50-70 = 1.14 CL40-50 + 2.56 (R2=0.997). estCL50-70 = 1.33 CL30-40 + 6.17 (R2=0.993)."

Amyloid PET • Clinical • Alzheimer's Disease • CNS Disorders

Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata. (PubMed, Dermatol Ther (Heidelb)) - P2b | "High levels of hair regrowth over a sustained period of time would be required to change AAPPO responses. Factors identified that may affect measurement of patient-reported psychosocial outcomes in AA included length of time since hair regrowth. Understanding factors that impact adaptation can help inform clinical practice and research."

Journal • Alopecia • Immunology

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial. (PubMed, J Dermatol) - "Ritlecitinib demonstrated clinical efficacy and acceptable safety over 48 weeks in Asian patients ≥12 years with AA and ≥50% hair loss. Results for the Asian subpopulation were consistent with the overall population in the ALLEGRO-2b/3 study."

Journal • P2/3 data • P2b data • Alopecia • Cardiovascular • Dermatology • Immunology • Infectious Disease • Oncology • Respiratory Diseases • Urticaria • JAK3

Timing of Initial Hair Regrowth and Clinical Trial-Defined Response: Results of an ALLEGRO 2b/3 Post-Hoc Analysis (AAD 2025) - "With recently approved therapies for severe AA, it is important to understand when patients receiving these treatments can expect therapeutic benefit after initial hair regrowth. We observed a substantial amount of time passes from initial hair regrowth until trial-defined clinical response is achieved, even among patients who experienced earlier SALT30 response. These results can help inform treatment expectations and goal setting between patients and their clinicians considering ritlecitinib therapy."

Clinical • Retrospective data • Alopecia • Immunology

Timing of Patient-Reported Outcome Response and Clinical Response: Results of an ALLEGRO 2b/3 Post-Hoc Analysis (AAD 2025) - "This post-hoc analysis characterized the timing between patient-reported outcome (PRO) response and initial clinical hair regrowth using integrated ALLEGRO trial data. Overall mean time to SALT30 after P-Sat response was 296.2 days (284.7, 386.9, 563.5 days across early, middle, and late responders). SALT30 was generally observed after PRO response, suggesting many patients receiving ritlecitinib perceive therapeutic benefit before SALT30-defined hair regrowth."

Clinical • Patient reported outcomes • Retrospective data • Alopecia • Immunology

Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata (AA): 3-year results from the ALLEGRO-LT phase 3, open-label study (AAD 2025) - P2b, P3 | "Ritlecitinib 50-mg demonstrated clinically meaningful clinician- and patient-reported efficacy through Month 36-38. These data are the longest duration of ritlecitinib treatment to be reported to date and support the long-term use of ritlecitinib in patients aged ≥12 years with AA."

Clinical • P3 data • Alopecia • Immunology

Intravenous lidocaine for gut function recovery in colonic surgery: a health economic evaluation of the ALLEGRO randomised clinical trial. (PubMed, BMJ Open) - "Intravenous lidocaine is not found to impact costs or health outcomes for patients undergoing colorectal surgery. In the absence of a clinical effect, disinvestment from perioperative lidocaine could save costs associated with infusion monitoring."

Clinical • HEOR • Journal • Anesthesia • Gastrointestinal Disorder

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. (PubMed, J Eur Acad Dermatol Venereol) - P2b, P3 | "Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration."

Journal • Alopecia • Immunology • JAK3

Δ-EGNN Method Accelerates the Construction of Machine Learning Potential. (PubMed, J Phys Chem Lett) - "In contrast to models directly trained on total energies, such as NequIP, MACE, and Allegro, the Δ-EGNN model employs delta-machine learning to predict the difference between energies derived from low- and high-level electronic structure methods, providing a significant advantage in reducing computational costs while preserving high accuracy. In summary, Δ-EGNN opens a new avenue for exploring energy landscapes and constructing machine learning potentials with afforable computational overhead, facilitating routine quantum mechanical calculations for complex molecular systems."

Journal

Curvilinear regression analysis and ranking of migraine treatment drugs using degree-based topological indices and the WASPAS method. (PubMed, Comput Biol Med) - "In this study, we calculate several degree-based topological indices for a range of migraine treatment medications, including aspirin, caffeine, eletriptan, ergotamine, sumatriptan, rizatriptan, verapamil, diclofenac, frovatriptan, and droperidol. This research emphasizes the application of curvilinear regression techniques and performs extensive testing using these models to enhance the understanding of drug properties. The Weighted Aggregated Sum Product Assessment (WASPAS) method is applied to evaluate and rank these drugs based on various topological indices attributes, integrating both the weighted sum model and the weighted product model to provide a comprehensive assessment."

Journal • CNS Disorders • Migraine • Pain

The effects of active and relaxing music on the short-term memory, attention and metabolic parameters of type 2 diabetes patients (T2DM). (PubMed, Med Pharm Rep) - "A two-day interventional, within-subject study was carried on 89 T2DM patients treated only with metformin and 67 age- and sex-matched control...The music listened to was the Allegro, respectively the Andante parts of 2 Mozart Sonatas...Our study highlighted the beneficial effect of music on metabolic and cognitive parameters, however, its impact depends on the type of music listened. Furthermore, cognitive scores of T2DM, especially in men, were less influenced by music than those of the control group."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial. (PubMed, J Dermatolog Treat) - P2b | "Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations. These results support a positive relationship between scalp hair regrowth and downstream PROs-including satisfaction and psychosocial burden-demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits."

Clinical • Journal • Alopecia • Immunology

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "In patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile with long-term treatment."

Journal • P3 data • Alopecia • Cardiovascular • Genetic Disorders • Herpes Zoster • Immunology • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases • Skin Cancer • Solid Tumor • Varicella Zoster

Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment. (PubMed, J Dermatol) - "Ritlecitinib benefits were calculated from the ALLEGRO-2b/3 clinical trial. These results, combined with the estimated differences in risks between the two doses, indicate that patients with AA value increases in the probabilities of scalp, eyebrow, and eyelash hair regrowth, with the average patient accepting increases in potential treatment-related risks for the 50-mg dose in exchange for higher efficacy than 30 mg. The DCE approach to measuring risk tolerance, combined with comparisons to expected benefit and risk differences, can be used to optimize AA treatment dose selection."

Journal • Alopecia • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • Thrombosis • JAK3

Bringing biomechanics to ballet: a feasibility study using wearable technology during grand allegro. (PubMed, Sports Biomech) - "Most dancers were symmetrical (90% to 110%) in limb loading (N = 8). Wearable technology was considered acceptable during ballet class, opening future exploration of the whole class, different classes and rehearsals, as well as potential use for returning dancers back from injury."

Journal

Symbiotic microbial population composition of Apolygus lucorum under temperature and pesticide pressures. (PubMed, Front Microbiol) - "Agathobaculum butyriciproducens, Advenella migardefenensis, and Akkermansia muciniphila were very sensitive to temperature and were strongly affected by temperature changes...The aim of this study is to reveal the dynamics and diversity of symbiotic bacteria of A. lucorum treated with imidacloprid at a range of temperatures. These results provide insight into new strategies for pest control in a changing climate."

Journal

Development of a panel of SNP loci in the emblematic southern damselfly (Coenagrion mercuriale) using a hybrid method: pitfalls and recommendations for large-scale SNP genotyping in a non-model endangered species. (PubMed, J Hered) - "In this study, we emphasise the difficulties of large-scale SNP genotyping in non-model species via a hybrid method that ultimately did not offer the expected cost and time saving compared to classical ddRAD approaches. However, SNPs showed greater power than previously available markers in identifying conservation units or admixture events, and the panel of reusable probes we describe here offers the potential to improve conservation efforts through future diachronic studies or finer estimations of key parameters like effective population size."

Journal

Revision of the subgenus Orientostichus Sciaky & Allegro in Southeast China, with descriptions of seven new species of the Pterostichus prattii Bates species group (Coleoptera: Carabidae: Pterostichini). (PubMed, Zootaxa) - "P. (O.) matalini Fedorenko, 2023 is newly recorded from China (Jian'ou, Fujian)."

Journal

Distribution of SALT scores during treatment with ritlecitinib for up to 24 months in the ALLEGRO phase 2b/3 and phase 3 extension trials in alopecia areata (JDP 2024) - No abstract available

P2/3 data • P2b data • P3 data • Alopecia • Immunology

Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. (PubMed, JAMA) - "The ALLEGRO trial was a randomized, placebo-controlled, double-blind trial conducted in 27 UK hospitals...Among patients undergoing elective minimally invasive colon resection, perioperative administration of 2% intravenous lidocaine did not improve return of gut function at 72 hours. isrctn.org Identifier: ISRCTN52352431."

Clinical • Journal • Surgery • Anesthesia

Reduced-Cost Genotyping by Resequencing in Peanut Breeding Programs Using Tecan Allegro Targeted Resequencing V2. (PubMed, Genes (Basel)) - "The results indicated that genotyping by a targeted resequencing approach reduced the cost from around USD 28 (SNP chip and GBS) to USD 18 per sample, while providing polymorphic markers with accurate SNP calls. With this cost-effective genotyping platform, pre-selected SNP markers can be used effectively and routinely for more breeding programs."

Journal

Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (PubMed, J Eur Acad Dermatol Venereol) - P2/3, P2a, P2b, P3 | "Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b/3 [NCT03732807], BRAVE-AA1 [NCT03570749] and BRAVE-AA2 [NCT03899259]) were included. We found similar efficacy between ritlecitinib 50 mg and baricitinib 4 mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA."

Journal • Review • Alopecia • Immunology

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial. (PubMed, Am J Clin Dermatol) - P2b | "The AAPPO instrument demonstrated the beneficial impact of ritlecitinib on patient-reported hair growth, which was consistent with improvements in clinician-reported outcomes."

Clinical • Journal • P2/3 data • P2b data • Alopecia • Immunology

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata. (PubMed, Br J Dermatol) - P2b, P3 | "Ritlecitinib has clinically meaningful and sustained efficacy beyond 1 year with a favourable safety and tolerability profile, supporting its long-term use in patients aged ≥12 years with AA."

Journal • P2/3 data • P2b data • P3 data • Alopecia • Immunology • JAK3